Search results for: Vaccines
Filter search results
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Not So Fast…
28 March 2019
…arrangements such as PAHOs revolving fund for vaccines which also carries a single and “favoured nation” type clause. If buyers A (wealthy large market) and B (poorer and smaller market)…
Adult Versus Adolescent Preferences for EQ-5D-Y Health States
15 April 2019
…for Economic Evaluation of Pediatric Vaccines: A Systematic Review. Value in Health, 19, pp.255-266. DOI. Kreimeier, S., Oppe, M., Ramos-Goñi, J.M., Cole, A., Devlin, N.J., Herdman, M., Mulhern, B., Shah,…
OHE Presents at Global AMR R&D Hub Board of Members Meeting in Paris
18 December 2019
…The advanced modelling approaches that are used for vaccines could be transferred to antibiotics to model the patterns of transmission and herd immunity. Contracting for new antibiotics needs to move…
Do child QALYs = adult QALYs? Five reasons why they might not
4 February 2020
…a wide range of child health care, including prevention (e.g. vaccines) and new treatments for childhood illness. An inability to capture QALYs for children in a way that makes them…
A Final MVAC Blueprint—and the Start of an R&D Revolution?
6 February 2020
…MVAC builds on the Advance Market Commitment (AMC) mechanism previously used in global health for pneumococcal vaccines. The MVAC has several important innovations and improvements. Most crucially, the MVAC is…
How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.
26 March 2020
…was given in Nov 2019; draft documents are expected in March /April 2020. Like the UK, Australia has high quality HTA valuation expertise for new vaccines and for new drugs….
H.R. 3 is the Wrong Policy for the Wrong Problem
10 September 2021
…of pre-existing mRNA platforms that allowed for the rapid development of COVID-19 vaccines. These positive externalities must be considered when evaluating a policy such as H.R. 3, which could have…
The CBO Doesn’t Understand Investors
13 September 2021
…have adverse consequences for population health—both in the US and globally. In the face of rapid scientific progress, such as we have seen with the development of COVID-19 vaccines and…
CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation
14 September 2021
…can be redeployed in lots of areas – for example the mRNA technology that underpins some of the successful Covid-19 vaccines was developed for use in cancer. Reductions in the…